Pharmacokinetics of LEO 43204 Gel in Actinic Keratosis Administered Under Maximal Use Conditions
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
This is an open-label, uncontrolled, non-randomised multi-centre trial in which 3 parallel
groups will be enrolled. The trial includes three active treatment groups. To be eligible for
inclusion in this trial, subjects must have at least 15 clinically typical, visible, and
discrete actinic keratosis (AKs) on the face, scalp or on the arm within a contiguous area of
approximately 250 cm2 of sun-damaged skin.
There will be 3 treatment groups: (1) once daily application of LEO43204 gel 0.018% on the
full face for three consecutive days, (2) once daily application of LEO43204 gel 0.1% on the
arm on a treatment area of approximately 250 cm2 for three consecutive days and , (3) once
daily application of LEO43204 gel 0.037 % on the scalp for three consecutive days.